How is the Allogene Therapeutics Inc today?

The Allogene Therapeutics Inc today is trading in the down by -4.31% at 1.11.

What is Allogene Therapeutics Inc Annual Revenue?

Allogene Therapeutics Inc Annual Revenue fell 76.84%, in the last year to $0.02 M. Its sector's average revenue growth for the last fiscal year was 8.76%.

What is Allogene Therapeutics Inc Annual Net Profit?

Allogene Therapeutics Inc Annual Net Profit rose 21.29% in the last year to $257.59 M. Its sector's average net profit growth for the last fiscal year was -11.04%.

What is Allogene Therapeutics Inc Price to Earning Ratio?

Allogene Therapeutics Inc Price to Earning Ratio is -0.96, which is negative.

What is Allogene Therapeutics Inc Stock Price?

Allogene Therapeutics Inc Stock Price fell 58.74% and underperformed its sector by 70.07% in the past year.

What is Allogene Therapeutics Inc Quarterly Net profit?

Allogene Therapeutics Inc Quarterly Net profit rose 8.1% YoY to $59.73 M. Its sector's average net profit growth YoY for the quarter was -212.78%.

What is Allogene Therapeutics Inc Debt to Equity Ratio?

Allogene Therapeutics Inc Debt to Equity Ratio of 0.21 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Allogene Therapeutics Inc Return on Equity(ROE)?

Allogene Therapeutics Inc Return on Equity(ROE) for the last financial year was -55.13%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Allogene Therapeutics Inc Mutual Fund Holding?

Allogene Therapeutics Inc Mutual Fund Holding decreased by 6.24% in the last quarter to 35.82.

What is Allogene Therapeutics Inc Promoter Share Holding?

Allogene Therapeutics Inc Promoter Share Holding decreased by 0.15% in the most recent quarter to 9.38%.

What is Allogene Therapeutics Inc Interest Coverage Ratio?

Allogene Therapeutics Inc Interest Coverage Ratio is -1419.7, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Allogene Therapeutics Inc Institutional Holding?

Allogene Therapeutics Inc Institutional Holding decreased by 5.04% in the last quarter to 74.5.

Allogene Therapeutics Inc XNAS: ALLO

Allogene Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Allogene Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Allogene Therapeutics Inc
Rating: 0.81708325
Author: Trendlyne DVM scores

about

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-c...

1.11 -0.05 (-4.31%)

70.63% Fall from 52W High

1.4M XNAS Volume

XNAS 21 May, 2025 5:30 PM (EDT)

Not Eligible

-

Expensive Valuation

13.3 / 100

Technically Bearish

19.4 / 100

8

1Yr Price target upside is 639%

10 analysts

Allogene Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Allogene Therapeutics Inc FAQ

How is Allogene Therapeutics Inc today?

Allogene Therapeutics Inc today is trading in the red, and is down by -4.31% at 1.11.

How has Allogene Therapeutics Inc performed historically?

Allogene Therapeutics Inc is currently trading down -4.31% on an intraday basis. In the past week the stock rose 16.84%. stock has been down -48.85% in the past quarter and fell -58.74% in the past year. You can view this in the overview section.